These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3221119)

  • 1. Pyrazinamide as a part of combination therapy for BL and LL patients--a preliminary report.
    Levy L
    Int J Lepr Other Mycobact Dis; 1988 Dec; 56(4):621-4. PubMed ID: 3221119
    [No Abstract]   [Full Text] [Related]  

  • 2. Pyrazinamide as a part of combination therapy for BL and LL patients--a preliminary report.
    Katoch K; Sreevatsa ; Ramanathan U; Ramu G
    Int J Lepr Other Mycobact Dis; 1988 Mar; 56(1):1-9. PubMed ID: 2453596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it safe to shorten multidrug therapy for lepromatous (LL and BL) leprosy to 12 months?
    Waters MF
    Lepr Rev; 1998 Jun; 69(2):110-1. PubMed ID: 9715594
    [No Abstract]   [Full Text] [Related]  

  • 4. Trials of daily, long-term minocycline and rifampin or clarithromycin and rifampin in the treatment of borderline lepromatous and lepromatous leprosy.
    Rea TH
    Int J Lepr Other Mycobact Dis; 2000 Jun; 68(2):129-35. PubMed ID: 11036492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
    Vijayakumaran P; Manimozhi N; Jesudasan K
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
    Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
    Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low.
    Gelber RH; Balagon VF; Cellona RV
    Int J Lepr Other Mycobact Dis; 2004 Dec; 72(4):493-500. PubMed ID: 15755209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampicin-induced erythema nodosum leprosum-like eruption in borderline lepromatous leprosy.
    Karthikeyan K; Thappa DM; Kadhiravan T
    Indian J Lepr; 2001; 73(2):167-9. PubMed ID: 11579653
    [No Abstract]   [Full Text] [Related]  

  • 10. Lymphocyte proliferation, IFN-gamma production and limiting dilution analysis of T-cell responses to ICRC and Mycobacterium leprae antigens in leprosy patients.
    Shinde SR; Chiplunkar SV; Butlin R; Samson PD; Deo MG; Gangal SG
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):51-8. PubMed ID: 8326181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silent iritis in treated bacillary negative leprosy.
    Thompson K; Job CK
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):306-10. PubMed ID: 8862265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guillain-Barré syndrome-like presentation in borderline leprosy with type-2 reaction.
    Rai VM; Shenoi S; Rao SN
    Dermatol Online J; 2006 Feb; 12(2):21. PubMed ID: 16638414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions.
    Ganapati R; Pai VV; Shroff HJ; Gandewar K
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):264-6. PubMed ID: 9251604
    [No Abstract]   [Full Text] [Related]  

  • 14. Interleukin-1 beta production by peripheral blood mononuclear cells from leprosy patients.
    Jayapal V; Bai GS; Lobo D; Thyagarajan SP
    Int J Lepr Other Mycobact Dis; 1993 Sep; 61(3):462-4. PubMed ID: 8228447
    [No Abstract]   [Full Text] [Related]  

  • 15. Borderline lepromatous leprosy presenting as a single cutaneous plaque.
    Armour KS; Scolyer RA; Barnetson RS
    Australas J Dermatol; 2005 Aug; 46(3):181-3. PubMed ID: 16008652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy.
    Zaheer SA; Mukherjee R; Ramkumar B; Misra RS; Sharma AK; Kar HK; Kaur H; Nair S; Mukherjee A; Talwar GP
    J Infect Dis; 1993 Feb; 167(2):401-10. PubMed ID: 8421173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two microbiological relapses in a patient with lepromatous leprosy.
    Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
    Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological assessment of dermal nerve damage occurring during multidrug therapy for leprosy.
    Jain M; Singh N; Bhatia A; Arora VK
    Int J Lepr Other Mycobact Dis; 2000 Jun; 68(2):167-71. PubMed ID: 11036497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapses during long-term follow up with drug-susceptible M. leprae among multibacillary leprosy patients treated with multidrug therapy regimens; case reports.
    Thomas A; Hari L; Nagarajan M; Prabhakar R
    Int J Lepr Other Mycobact Dis; 1995 Sep; 63(3):391-4. PubMed ID: 7594922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
    Kumar A; Girdhar A; Girdhar BK
    Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.